Eli Lilly: Still Expensive As Earnings Near, But Not Worthy Of A Downgrade
Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.
Exclusive: Arianna Huffington’s Thrive Global inks novel partnership with pharma giant Eli Lilly
Last year, Thrive Global teamed up with OpenAI to create Thrive AI Health, an AI-powered health coach trained on the ...
Is Eli Lilly and Company (LLY) the Best Blue Chip Stock to Buy for 2025?
We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at ...
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
FiercePharma9d
Lilly’s Zepbound expected to surpass Novo’s Wegovy to ‘dominate’ obesity market: GlobalData
The company is also testing tirzepatide in heart failure ... said in the report. “Now with Zepbound, the revolution ...
The Armenian Reporter1h
Eli Lilly and Company (NYSE:LLY) Trading Up 1.7% – Still a Buy?
Eli Lilly and Company (NYSE:LLY – Get Free Report) shot up 1.7% during mid-day trading on Thursday . The company traded as high as $792.56 and last traded at $786.15. 3,476,307 shares traded hands ...
Yahoo Finance2d
Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with ...